Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696759 · ClinicalTrials.gov registry record · NA
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
A NA study, sponsored by University of Arkansas.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT02696759 is a NA study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 15 participants.
The verdict
NCT02696759, a NA study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria and other microorganisms living in the gut. In turn, the activities of these immune cells could work with anti-cancer therapies to make them more, or less, effective.
Interventions
- OTHER Blood & Fecal Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696759
The ClinicalTrials.gov registry entry for NCT02696759 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood & Fecal Collection is the first listed.
NCT02696759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02696759 about?
NCT02696759 is a clinical study titled "Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer". The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria and other microorganisms living in the gut. In turn, the activities of th...
What is the current status of trial NCT02696759?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2016-07. Estimated completion is 2021-08.
What interventions are being tested in trial NCT02696759?
The interventions under investigation include: Blood & Fecal Collection (OTHER).
Who is sponsoring clinical trial NCT02696759?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.